MatsukiyoCocokara & Co (3088) Q1 2027 earnings summary

Executive summary

• Net sales rose 5.7% year-over-year to ¥289,348 million for the quarter ended June 30, 2026, with operating profit up 8.5% to ¥21,487 million and profit attributable to owners of parent up 14.9% to ¥14,865 million.

• The company advanced its differentiation, investment, and sustainability strategies, including expanding its store network, investing in digital and operational infrastructure, and enhancing private brand offerings.

• Two new subsidiaries, UNIVERSAL DRUG CO., LTD. and AppBrew Inc., were added to the consolidation scope, supporting growth and platform expansion.

Financial highlights

• EBITDA increased 8.9% year-over-year to ¥27,662 million; ordinary profit rose 8.8% to ¥22,822 million.

• Gross profit improved to ¥103,375 million from ¥94,283 million year-over-year.

• Basic earnings per share increased to ¥37.59 from ¥32.30 year-over-year.

• Comprehensive income grew 14.3% to ¥14,345 million.

Outlook and guidance

• Full-year net sales forecast at ¥1,155,000 million (up 3.4% year-over-year), with profit attributable to owners of parent projected at ¥59,000 million (up 5.8%).

• No revisions to previously announced earnings or dividend forecasts.